In addition to reducing tumor burden, BRAF/MEKi potentially modulate the immunosuppressive tumor microenvironment including antigen presentation, secretion of cytokines, and the ratio of suppressive versus effector tumor-infiltrating lymphocytes in BRAFV600-mutated tumors.25,28,29 We did not find that adverse events were associated with better survival, including toxicity from prior immunotherapy, or toxicity during BRAF/MEKi treatment. The gene discussed is BRAF; the disease is neoplasm.